Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Rhabdomyosarcoma 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangiopericytoma, Malignant 1Fibrosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Doxorubicin 11Ifosfamide 10Radiotherapy 7pazopanib 4Imatinib Mesylate 3Filgrastim 3Etoposide 3Epirubicin 3Chemotherapy, Adjuvant 3Bevacizumab 3cixutumumab 2carotuximab 2belinostat 2Vincristine 2Sunitinib 2Sorafenib 2Radiotherapy, Conformal 2Paclitaxel 2Gemcitabine 2Dactinomycin 2Cyclophosphamide 2Carboplatin 2tremelimumab 1trebananib 1temsirolimus 1soblidotin 1romidepsin 1ribociclib 1regorafenib 1perifosine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hemangiosarcoma × soblidotin × Clear all
NCT00064220 2012-05-16

Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma

Daiichi Sankyo

Phase 2 Completed
Sarcoma

Hemangiopericytoma, Malignant, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡